These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 3275063)

  • 1. Cost of therapy should be considered in accruing patients into clinical trials.
    Lawrence G
    Oncology (Williston Park); 1988 Sep; 2(9):17. PubMed ID: 3275063
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost of clinical trials in cancer.
    Snyder RD; Burns WI
    Aust Health Rev; 1982 May; 5(2):27-8. PubMed ID: 10256885
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook.
    J Natl Cancer Inst Monogr; 1998; (24):1-28. PubMed ID: 9704318
    [No Abstract]   [Full Text] [Related]  

  • 4. Does managed care jeopardize cancer research?
    Jenks S
    J Natl Cancer Inst; 1995 Aug; 87(15):1102-6. PubMed ID: 7674309
    [No Abstract]   [Full Text] [Related]  

  • 5. Enrollment of older persons in cancer trials after the medicare reimbursement policy change.
    Gross CP; Wong N; Dubin JA; Mayne ST; Krumholz HM
    Arch Intern Med; 2005 Jul; 165(13):1514-20. PubMed ID: 16009867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stat bite: State mandates for insurance coverage of clinical trials.
    J Natl Cancer Inst; 2003 Sep; 95(17):1269. PubMed ID: 12953077
    [No Abstract]   [Full Text] [Related]  

  • 7. Taking quality of life into account in health economic analyses.
    Weeks J
    J Natl Cancer Inst Monogr; 1996; (20):23-7. PubMed ID: 8750463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using patients as their own controls for cost evaluation of phase I clinical trials.
    Sherman EJ; Rubin DM; Venkatraman E; Schwartz GK; Miller VA; Radzyner MH; Ruchlin HS; Spriggs D; Pfister DG
    J Clin Oncol; 2004 Apr; 22(7):1308-14. PubMed ID: 15051779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
    Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
    Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to clinical trial enrollment: are state mandates the solution?
    Hillner BE
    J Natl Cancer Inst; 2004 Jul; 96(14):1048-9. PubMed ID: 15265958
    [No Abstract]   [Full Text] [Related]  

  • 12. Gore champions major new cancer initiative.
    Castellucci L
    J Natl Cancer Inst; 1998 Feb; 90(4):270. PubMed ID: 9486811
    [No Abstract]   [Full Text] [Related]  

  • 13. Eastern Cooperative Oncology Group (ECOG).
    Fairclough DL; Cella DF
    J Natl Cancer Inst Monogr; 1996; (20):73-5. PubMed ID: 8750470
    [No Abstract]   [Full Text] [Related]  

  • 14. Researchers facing increasing costs for clinical research, with few solutions.
    Erdmann J
    J Natl Cancer Inst; 2005 Oct; 97(20):1492-4. PubMed ID: 16234558
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Information by the German Cancer Society].
    Drings P
    Geburtshilfe Frauenheilkd; 1996 Oct; 56(10):M164-6. PubMed ID: 9036060
    [No Abstract]   [Full Text] [Related]  

  • 17. Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
    Aapro MS; Köhne CH; Cohen HJ; Extermann M
    Oncologist; 2005 Mar; 10(3):198-204. PubMed ID: 15793223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Researching the cost of research.
    Wright JR; Levine MN
    J Clin Oncol; 2003 Nov; 21(22):4081-2. PubMed ID: 14559890
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer carve outs and outcomes measurement programs: an emerging paradigm.
    Kurowski B
    Med Interface; 1996 Nov; 9(11):81-4. PubMed ID: 10162564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of quality-of-life research in Southwest Oncology Group trials.
    Moinpour CM
    J Natl Cancer Inst Monogr; 1996; (20):11-6. PubMed ID: 8750461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.